medigraphic.com
ISSN 2594-3006 (Electronic)
ISSN 2007-1752 (Print)
Archivos de Medicina de Urgencia de México

2025, Number 1

<< Back

Arch Med Urg Mex 2025; 17 (1)

Recommendations for high-flow oxygen therapy in the emergency department PART 2

Sanabría-Cordero D, Trejo-Rosas S, Mendez-Jesus IA, Mendoza-Portillo E, Russi Hernández M

Language: Spanish
References: 35
Page: 58-68
PDF size: 965.06 Kb.


ABSTRACT

The approach to acute respiratory failure is an emergency in any hospital unit since the early or late start of its treatment will have a significant impact on the prognosis of patients, for this reason a review of the use of high flow oxygen therapy (HFOT) in different clinical scenarios was carried out; in this article we will address acute respiratory failure type 1 or hypoxemic (ARF type 1), acute respiratory failure type 2 or hypercapnic (ARF type 2) and the different algorithms of oxygen support through high flow nasal cannulas (HFNC) in posextubation and postsurgical patients who require HAFT.


REFERENCES

  1. Nishimura M. High-flow nasal cannula oxygen therapy in adults:physiological benefits, indication, clinical benefits, and adverseeffects. Respir Care. 2016;61(4):529-541.

  2. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinicalimplications. Chest. 2015;148(1):253-261.

  3. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasalcannula in acute hypoxemic respiratory failure. N Engl J Med.2015;372(23):2185-2196.

  4. Roca O, Riera J, Torres F, Masclans JR. High-flow oxygen therapyin acute respiratory failure. Respir Care. 2010;55(4):408-413.

  5. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidifiedhigh flow nasal oxygen in critical care patients: a prospectivepilot study. Intensive Care Med. 2011;37(11):1780-1786.

  6. Lee MK, Choi J, Park B, et al. High-flow nasal cannula therapyin acute hypoxemic respiratory failure: a randomized clinicaltrial. Respir Care. 2016;61(3):291-299.

  7. Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-flow versusVenturi mask oxygen therapy after extubation. Am J Respir CritCare Med. 2014;190(3):282-288.

  8. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure.Lancet. 2009;374(9685):250-259.

  9. Pisani L, Vega ML. Use of nasal high flow in stable COPD: rationaleand physiology. COPD. 2017;14(3):346-350.

  10. Cortegiani A, Longhini F, Madotto F, et al. High flow nasal therapyversus conventional oxygen therapy in patients with acute respiratoryfailure: a systematic review and meta-analysis. J Crit Care.2019;50:197-204.

  11. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns ofCare, and Mortality for Patients With Acute Respiratory DistressSyndrome in Intensive Care Units in 50 Countries. JAMA.2016;315(8):788–800.

  12. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009pandemic influenza A virus and bacterial coinfection in the UnitedStates. Crit Care Med. 2012;40(5):1487–1498.

  13. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acuterespiratory distress syndrome: is a different approach to managementwarranted? Lancet Respir Med. 2020;8(8):816–821.

  14. Roca O, Messika J, Caralt B, et al. Predicting success of high-flownasal cannula in pneumonia patients with hypoxemic respiratoryfailure: The utility of the ROX index. J Crit Care. 2016;35:200–205.

  15. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasalcannula in acute hypoxemic respiratory failure. N Engl J Med.2015;372(23):2185–2196.

  16. Prakash J, Bhattacharya PK, Singh N, et al. Usefulness of ROXindex in prediction of need for invasive mechanical ventilation inpatients with COVID-19 pneumonia. J Anaesthesiol Clin Pharmacol.2021;37(1):88–93.

  17. (***) Bos LD, Artigas A, Constantin J-M, et al. Precision medicinein acute respiratory distress syndrome: workshop report andrecommendations for future research. Eur Respir Rev 2021; 30:200317.

  18. Bell N, Hutchinson CL, Green TC, et al. Randomised control trialof humidified high flow nasal cannulae versus standard oxygenin the emergency department. Emerg Med Australas 2015; 27:537–541.

  19. Lemiale V, Mokart D, Mayaux J, et al. The effects of a 2-h trial ofhigh-flow oxygen by nasal cannula versus Venturi mask in immunocompromisedpatients with hypoxemic acute respiratory failure:a multicenter randomized trial. Crit Care 2015; 19: 380.

  20. Rittayamai N, Tscheikuna J, Praphruetkit N, et al. Use of high-flownasal cannula for acute dyspnea and hypoxemia in the emergencydepartment. Respir Care 2015; 60: 1377–1382

  21. Jones PG, Kamona S, Doran O, et al. Randomized controlled trialof humidified high-flow nasal oxygen for acute respiratory distressin the emergency department: the HOT-ER Study. Respir Care2016; 61: 291–299.

  22. Makdee O, Monsomboon A, Surabenjawong U, et al. High-flow nasal cannula versus conventional oxygen therapy inemergency department patients with cardiogenic pulmonaryedema: a randomized controlled trial. Ann Emerg Med 2017;70: 465–472.

  23. Azoulay E, Lemiale V, Mokart D, et al. Effect of high-flow nasaloxygen vs standard oxygen on 28-day mortality in immunocompromisedpatients with acute respiratory failure: the HIGH randomizedclinical trial. JAMA 2018; 320: 2099–2107.

  24. Grieco DL, Menga LS, Eleuteri D, et al. Patient self-inflicted lunginjury: implications for acute hypoxemic respiratory failure andARDS patients on non-invasive support. Minerva Anestesiol 2019;85: 1014–1023.

  25. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannulafor acute hypoxemic respiratory failure in patients with COVID-19:systematic reviews of effectiveness and its risks of aerosolization,dispersion, and infection transmission. Can J Aneasth 2020; 67:1217–1248.

  26. Ferioli M, Cisternino C, Leo V, et al. Protecting healthcare workersfrom SARS-CoV-2 infection: practical indications. Eur Respir Rev2020; 29: 200068.

  27. Franco C, Facciolongo N, Tonelli R, et al. Feasibility and clinical impactof out-of-ICU noninvasive respiratory support in patients withCOVID-19-related pneumonia. Eur Respir J 2020; 56: 2002130.

  28. Junhai Z, Jing Y, Beibei C, Li L. The value of ROX index in predictingthe outcome of high flow nasal cannula: a systematic reviewand meta-analysis. Respir Res. 2022 Feb 17;23(1):33. doi:10.1186/s12931-022-01951-9.

  29. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructivepulmonary disease. N Engl J Med. 2019;381(13):1257–66.

  30. MacIntyre NR. Pathophysiology of acute respiratory failurein chronic obstructive pulmonary disease. Respir Care.2008;53(6):649–57.

  31. Piper AJ, Grunstein RR. Obesity hypoventilation syndrome:mechanisms and management. Am J Respir Crit Care Med.2011;183(3):292–8.

  32. Ergan B, Oczkowski S, Rochwerg B, et al. European RespiratorySociety guidelines on noninvasive respiratory support in acute respiratoryfailure. Eur Respir J. 2021;58(6):2101149.

  33. Spicuzza L, Schisano M: High-flow nasal cannula oxygen therapyas an emerging option for respiratory failure: the present and thefuture. Ther Adv Chronic Dis. 2020, 13:2040622320920106

  34. Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G,et al. Physiologic effects of high-flow nasal cannula in acutehypoxemic respiratory failure. Am J Respir Crit Care Med.2017;195(9):1207-1215. doi:10.1164/rccm.201605-0916OC

  35. Parke R, McGuinness S, Eccleston M: Nasal high-flow therapydelivers low level positive airway pressure . Br J Anaesth. 2009,103:886-890.




2020     |     www.medigraphic.com